These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 11107905)

  • 21. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
    Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
    Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation.
    Dis Markers; 1990; 8(2):105-7. PubMed ID: 1696869
    [No Abstract]   [Full Text] [Related]  

  • 26. A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9.
    Raya NE; Quintana D; Carrazana Y; Gómez CE; Duarte CA
    Vaccine; 1999 Jun; 17(20-21):2646-50. PubMed ID: 10418914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B and T cell reactivities after immunization of macaques with HIV subcomponents.
    Wahren B; Chiodi F; Ljunggren K; Putney S; Kurth R; Gallo RC; Fenyö EM
    AIDS Res Hum Retroviruses; 1988 Jun; 4(3):199-210. PubMed ID: 3260790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes.
    Michel ML; Mancini M; Schlienger K; Tiollais P
    Res Virol; 1993; 144(4):263-7. PubMed ID: 7692575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenic combinations of HIV-1 B- and heterologous T-cell epitopes.
    Isaguliants M; Rudén U; Gilljam G; Wahren B
    Immunol Lett; 1994 Oct; 42(3):173-8. PubMed ID: 7534271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.
    Berkower I; Smith GE; Giri C; Murphy D
    J Exp Med; 1989 Nov; 170(5):1681-95. PubMed ID: 2478654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse/human chimeric anti-HIV-1 gp120 antibody to the principal neutralizing determinant: tolerability and pharmacokinetics in cynomolgus monkeys, Macaca fascicularis.
    Liou RS; Fung MS; Zühlke U; Gudat F; McKinney S; Gordon W; Bee W; Botta L; Gygax D; Chang TW
    Biotherapy; 1992; 5(4):291-9. PubMed ID: 1283953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Design of virus-like particles, exposing HIV-1 epitopes].
    Lebedev LR; Karpenko LI; Poryvaeva VA; Azaev MSh; Riabchikova EI; Gileva IP; Il'ichev AA
    Mol Biol (Mosk); 2000; 34(3):480-5. PubMed ID: 10867928
    [No Abstract]   [Full Text] [Related]  

  • 33. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
    Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG
    Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The multi-epitope polypeptide approach in HIV-1 vaccine development.
    Cano CA
    Genet Anal; 1999 Nov; 15(3-5):149-53. PubMed ID: 10596755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neutralizing antibodies to 5 HIV-1 strains in macaques immunized with the multi-epitope polypeptide TAB9].
    Navea Leyva LM; Lobaina Bartelemy L; Dubed Echevarría M; Alvarez Seguí G; Gómez Rodríguez C; Duarte Cano C
    Rev Cubana Med Trop; 2000; 52(2):115-8. PubMed ID: 11107905
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.